Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Spike
40%
Omicron Coronavirus Variant
30%
Adoptive Immunity
28%
COVID-19
26%
Breakthrough Infection
22%
Neutralizing Antibody
19%
Booster Dose
17%
Immunosuppressive Therapy
14%
Immune-Mediated Inflammatory Diseases
14%
Hybrid Immunity
14%
Human Immunodeficiency Virus 1
14%
Immunotherapy
14%
Comorbidity
14%
Titer
8%
T Cell
6%
Humoral Immunity
5%
Cytotoxic T-Cell
5%
CD20 Antibody
5%
Fingolimod
5%
Keyphrases
COVID-19
28%
Vaccination
18%
Vaccine-induced Immunity
18%
Antibody Level
17%
Vaccine Response
14%
Functional Cure
14%
Human Immunodeficiency Virus Type 1 (HIV-1)
14%
SARS-CoV-2 Vaccine
14%
Longitudinal Assessment
14%
T Cell Immunity
14%
Hybrid Immunity
14%
Omicron Infection
14%
BA.2
10%
Antiretroviral Therapy
8%
Vaccine Dose
7%
Serum IgE
7%
IgG Levels
6%
Immune Checkpoint Pathway
6%
Broadly Neutralizing Antibodies
6%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
6%
Anti-spike IgG
5%
Heterologous Vaccination
5%
Biochemistry, Genetics and Molecular Biology
SARS Coronavirus
42%
Cellular Immunity
28%
Cohort Study
17%
Spike
16%
Isoform
14%
Alternative Splicing
14%
Cancer Cell
14%
Omicron
14%
Comorbidity
14%
Programmed Cell Death 1
11%
T Cell
10%
Immune Checkpoints
9%
CD4
7%
PD-L1
7%
CD8
5%
Humoral Immunity
5%